Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
need diamond hands AEZS
Dogecoin will hit 9/7cent and bounce to 16/18.. AEZS is ready for a 150
again the only thing needed here is patience,god bless all
we will win this one , we need time , flu season is in the fall , November rain AEZS
u have alot of issues with AEZS give it a rest
The issue is that AEZS does not own the product at all…
A research team at the University of Würzburg is testing a novel approach for a vaccine against the coronavirus - for swallowing. The advantages: Comparatively cheap to produce, easy to administer and relatively stable even at normal temperatures.
If Prof. Thomas Rudel from the Julius Maximilians University of Würzburg and the biopharmaceutical company Aeterna Zentaris in Frankfurt have their way, there could possibly be significant reinforcements in the fight against the global corona pandemic in the future: a vaccination that does not come with the syringe rather than as a capsule that can easily be swallowed. Preclinical development has already started.
Thomas Rudel holds the chair for microbiology at the Julius Maximilians University of Würzburg (JMU) and had the idea for oral vaccination a good year ago Typhoid infection is at work ". The oral typhoid vaccine is based on a special strain of bacteria, Salmonella Typhi Ty21a.
Rudel and the scientists in his laboratory are now also working with this bacterial strain - with a significant modification: "We have programmed the bacteria to produce SARS-CoV-2 antigens," explains the microbiologist. Rudel was supported by the microbiologist Dr. Birgit Bergmann. Protected from gastric acid attack in a capsule, the bacteria are supposed to develop their effect in the human small intestine after passing through the stomach. The scientific approach assumes that the bacteria can present the antigens to the immune system there.
"Special cells in the intestinal wall are supposed to ensure that bacteria and the antigens are absorbed by immune cells and transported further into lymphoid tissue," says Rudel. There they could in turn activate other cells of the immune system - so-called B and T cells - and set an immune response in motion. Rudel hopes that, if successful, this immune response will be so strong that all human mucous membranes will be put on alert and, as a result, coronaviruses will be prevented from entering the body there.
The advantages are obvious
In order to remain effective against newly emerging virus mutations, Rudel's team developed the bacteria in such a way that they produce not one, but two antigens at the same time. So if one antigen is only weakly effective due to a virus change, the second antigen could serve as a “safety anchor”: It is based on a gene that has been shown to mutate only rarely.
The vaccine from the Franconian laboratory would also have several advantages: It would be cheap to manufacture, easy to administer and relatively stable even at normal temperatures.
Optimistic as well as realistic
The development of the vaccine strains and the preclinical work is financially supported by Aeterna Zentaris GmbH. The pharmaceutical company would undertake the subsequent clinical tests. Rudel is confident that the necessary permits could be obtained relatively quickly. A few years ago, Aeterna Zentaris had been working with a similar process on a vaccine against prostate cancer, which was about to start clinical trials and had been officially approved for clinical examination. The team can now build on these experiences.
Nevertheless, Rudel is cautiously optimistic. There is no guarantee thbat an oral vaccination against Covid-19 will soon be available in pharmacies, warns Rudel. After all, many active ingredients have failed even at a late stage of development because they were not sufficiently effective or had unexpected and undesirable effects.
yep u got it , we will win this one too AEZS
Nothing else matters , diamond hands AEZS
We r close 5x AEZS
i still say aezs and tmdi are so underpriced considering whats coming for both of them ,i bought some of that stock u spoke of,hold this little gem till big news hits,god bless and good luck to us
i just got a black walnut cutting board for 90 bucks , sweet deal as I type a squirrel just ran over my roof , life is good AEZS has the chance to do good
for f sake i got shares at 80 cent , management paid 142
u got it champ I took your word and my intuition and bet large AEZS
another week , bad week AEZS needs clariedy for sure
another of my picks is GILT will do well in the future
another of my picks is GILT will do well in the future
Bought a boat load of stuff off amazon knives axe food clothes lol spent like 2k all delivered sha zam AEZS will as well deliver
agree think we rocket next uptick AEZS
not anymore with klauss in charge,look at all he has acclomplished in 2 short yrs,look at all th new licensing deals,finalpedi trial for test started which again is for an unmet need and all the potential other uses for macrilen,im talking from experience as i was once down 90 plus % in aezs before klauss took over,give him another 3 months tops and u will see some of these catalysts come to fruition and pps will blow past 5 minimum,no raises till 2023,50 mill in bank min and 150 mill float max altogether with options included,low burn rate,to say pedi test will be a flop is absolutely crazy as again its for an unmet need where the adult test was not,still the key here is other uses for macrilen like tbi,cancer cachexia which are in phase 3 in usa but aezs keeping it quiet for some reason,maybe because novo owns rights in n america unlike row where aezs only licensed the test,if macrilen gets approved in usa for these uses klauss will use that data for eu approval where we own all the rights and we still gt a % of sales in n america of all these uses but the main thing is klauss will use data from fda to get approval in eu like we did adult test,it would take multiple major disasters to ruin this and im not even including all the other preclinicals going on like macrilen for lou gehgrigs disaease and all the new licensing deals,covid pill vaccine alone will send this to 5 and more,again only thing needed here is patience,god bless all and good luck to us,again way too many positive different catalysts coming,just hold
I hope you are wrong, but your saying is well supported by company’s track record which is pathetic. Management creditability issue!
again pedi test is for an unmet need,hardly worthless,macrilen will have many uses besides a test like tbi ,cancer cachexia,both in phase 3 in usa,lou gehrigs disease preclinicals,this is far from worthless bro,god bless all
folks just wait and we win... hold, diamond hands AEZS
I bought RXMD , CLOV, PLUG, BTG, ZHUD this year and made money AEZS waiting
yes like lightning 0.8850-0.0199 (-2.20%)
like the other pr cher have issued a bolt of lightning .... ua crazy climb ... hear here the only news is that they sell the company and recover something .... failed
U r here bc u have tickets , it will go up like lightening quick and u know it ,so shut it AEZS
I don't think this vaccine will see the light Pfizer in germany has a plant to create millions and millions of doses ... do you think a multinational like pfizer is hindered by mister bucket?
second point ... now the approved vaccines have almost covered a large slice of the European population ... well that goes a and z will bring the end of phase three in a few have .. what value can it have ...
always and if these preclinics are successful, which given the prolongation of time makes me more and more doubt ...
Now I have decided on the next return on the dollar I sell and I forget about these failures forever and good luck to all ....
but if it takes 4 years to bring an approved test to market, imagine a clinical study on a vaccine ...
This company is just a salary for management .... for too many years and I don't want to be comfortable with this crap anymore
I hope I'm wrong .... but reality is proving me right ... all the announcements made = 0 while other biotechs without news are running ... why? because there is no value here
you said well, if something materializes ..
we remove phase three of the test on children which, as for adults, is worth nothing ...
the price reflects the value of the company and for what they have the market is evaluating it at 0.9 and lower and each pop is only for opter to start selling short higher.
sorry but i don't see all this value here ....
we have been waiting for the authorization for sale in europe for 4 years ... this says a lot about the skills of this management
U serious. Look at the last prospectus. Many preclinicals going on. Macrilen in 2 different phase 3 trials in usa for tbi and cancer cachexia. Lou gehrig disease preclinicals for macrilen. Covid pill vaccine preclinicals. Final trials for pedi approval for test which is for an unmet need. Growth hormone is getting worse not better and I left out like 3 or 4 other preclinicals. This will be an easy 10 bagger if even a third of all these different catalysts come to fruition. All that is needed here is patience. God bless all
for 15 years we have been paying their salaries ... you are too sure about a company xhe has nothing to offer ... if it were this fantastic company the price would not be different ??? they are all stupid not to buy this stuff ... we screwed up ... they have nothing a test? and then??? what are these catalysts ???
good load up than , these bunch of clowns will pay
Tried to average down, when I believed they had something to offer. Everytime I bought another 1000 shares it dropped again. Now tired of trying to keep averaging down and still stuck unless I want to lose 3k. But I'm close to cutting my losses, if it gets back to 1.00, I'm out
OK and you are a Doctor or Scientist..WE all don't KNOW what will Happen in the Future ..
and this future is made of macrilen thing ??? to 3 million a year ... spendenfone 20 ... good future it is better that they stay still perhaps
Hey is the Price to high...past IS past WE Look ino the Future ...
Then why did you buy 6000 shares?
I agree the macrilen is not worth anything they spent hundreds of millions of dollars for a test that takes not even 3 a year ... pathetic and the most pathetic thing is that to continue to take the salary they continue with this crap but the market does not believe more after 15 years ... of failures and wasted money .... then one can believe in fairy tales but the reality is this ... an incapable management with a worthless test ....
if they do not hurry with this covid pill they will be wiped out ... and since in the past they have already tried with a prostate cancer vaccine with the same mechanism ... obviously failed ... the doubts are there. a very pathetic management. 3 pr ... and not even a minimum of interest ... yes the price is too high ...
Followers
|
300
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18786
|
Created
|
05/09/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |